The salicylates have been used in the symptomatic treatment of rheumatic disorders for over 50 years. They are capable of producing a striking change in the clinical picture of acute rheumatic fever and possess a smaller, but still definite, effect in rheumatoid arthritis. Their value as suppressive drugs appears to be concerned with alleviating the symptoms produced by the inflammatory processes which form a major part of the reaction of the body in rheumatic disease. The (Hailman, 1952; Roskam, 1956; Done, Ely, and Kelley, 1958) . The purpose of the present article is to show that the available evidence, if examined critically, fails to provide convincing proof of the validity of the hypothesis that the therapeutic actions of salicylates in rheumatism are mediated by the adrenal cortex or its hormones.
If salicylates act through the adrenal cortex, they may do so in one or more of three ways:
(1) They stimulate the anterior pituitary to secrete adrenocorticotrophin, which in turn causes the adrenal cortex to produce corticosteroids.
(2) They have an adrenocorticotrophic action. Kovacs, 1950) , and histological changes suggestive of adrenal hypersecretion (Robinson, 1951; Champy and Demay, 1951; Tronchetti and Nello, 1952) . More direct evidence of pituitary and adrenal stimulation has been provided by the increased amounts of ACTH (Eades and King, 1953) and of adrenal steroids found in the plasma (Van Cauwenberge, 1954 ; Good, Done, Ely, and Kelley, 1957) and urine (La Barre and Hans, 1954 ) of animals treated with salicylates. Hypothalamic centres are also concerned because pretreatment with pentobarbital (Cronheim and Hyder, 1954) or previous destruction of the median eminence of the hypothalamus (George and Way, 1957) (Bayliss and Steinbeck, 1954; Smith, Gray, and Lunnon, 1954; Done, Ely, and Kelley, 1955; Kelley, Ely, Done, and Ainger, 1955; Peterson, Black, and Bunim, 1958) . Increased plasma levels of circulating 17-hydroxysteroids have been reported to occur in children with salicylate intoxication (Done, Ely, and Kelley, 1954) . This result is compatible with the animal work in that it must represent an adrenal response to stress of a toxic and non-specific nature.
The most pertinent objection to any hypothesis involving the participation of the pituitary adrenal axis in the anti-rheumatic actions of salicylates is provided by the reports that the drugs exert their anti-inflammatory effects in patients with Addison's disease (Thorn, 1958) , in a rheumatoid arthritic patient whose adrenal function had been either markedly or completely suppressed (Peterson and others, 1958) , and in adrenalectomized and hypophysectomized animals (Ungar, Damgaard, and Hummel, 1952) . This data also serves to vitiate the suggestion that salicylates may have a direct adrenocorticotrophic action. Additional evidence against this mechanism is that hypophysectomy abolishes most of the responses suggestive of adrenal cortical stimulation, which are elicited by salicylates in normal animals (cf. Done and others, 1958) .
There remains the possibility that salicylates may either reinforce or mimic the actions of the natural adrenal steroids on the tissues. Done and others (1958) Kelemen (1956) has shown that there is no synergism between the inhibitory effects of salicylates and hydrocortisone on experimentally induced oedema in the rat, which is against the suggestion that salicylate may increase the tissue response to adrenal steroids.
If salicylates either reinforce or mimic the actions of the natural hormones then they should produce very similar, if not identical, effects on metabolism. However, important differences have been described. It has been clearly shown that therapeutic doses of salicylate cause a marked and progressive increase of oxygen consumption in normal subjects and in patients with acute rheumatic fever and subacute rheumatism (Cochran, 1952; 1954) . The relief of symptoms in the rheumatic patients appeared to be associated with the maintenance of the increased oxygen uptake. Hydrocortisone does not produce similar increases in the metabolic rate (Hetzel, Williams, and Lander, 1957) . Salicylates have been found to reduce the hyperglycaemia and glycosuria of patients with diabetes mellitus and of experimentally diabetic animals, whereas cortisone and other adrenal steroids produce the reverse effects (Ingle, 1950; Smith, Meade, and Bornstein, 1952;  Dibenedetto dell'Aquila and Angarano, 1954; Reid, Macdougall, and Andrews, 1957) . The administration of cortisone causes liver glycogen deposition in adrenalectomized animals, and hyperglycaemia and glycosuria in normal rats. but these effects are inhibited by the concurrent administration of salicylates (Smith, 1952b) . The different, opposite, and even antagonistic effects of salicylates and adrenal steroids cannot be reconciled with any mechanism which assumes that the two groups of drugs have the same fundamental actions on the peripheral tissues.
Summary
The possible mechanisms by which the therapeutic effects of salicylates in rheumatism could be mediated by the adrenal cortex and its hormones are discussed. It is concluded that the administration of large amounts of salicylates to experimental animals and to man may produce a stimulation of the pituitary-adrenal axis leading to an increased secretion of adrenal steroids. However, this stimulation represents a pituitary-adrenal response to stress of a toxic and non-specific nature, and is not concerned as a mediator in the antiinflammatory effects of therapeutic doses of salicylates. The 
